Physician Assistant · Lakewood, NJ
NPI
1285748897
Since 2006
Specialty
Physician Assistant
Code 363A00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
150 E Kennedy Blvd
Lakewood, NJ, 08701
Phone (732) 364-0515
Groups this clinician bills Medicare through
Medicare paid, 2024
$306K
7,927 services
Medicare patients, 2024
1,666
Average age 75
Drug cost, 2024
$976K
1,637 prescriptions
Company payments, 2025
$2,125
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark A Mazak was code 17003 (destruction skin lesion), 3,273 times for 520 patients. In total Mark A Mazak billed 7,927 services in 48 codes, and Medicare paid $306K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 3,273 | 520 | $4.31 | $14K |
| 99213 Office E&M - Established | Office | 1,342 | 1,015 | $54.59 | $73K |
| 17000 Destruction Skin Lesion | Office | 860 | 675 | $37.30 | $32K |
| 99214 Office E&M - Established | Office | 627 | 455 | $80.24 | $50K |
| 11102 Skin Biopsy | Office | 467 | 418 | $61.94 | $29K |
| 17004 Destruction Skin Lesion | Office | 204 | 156 | $105.86 | $22K |
| 99203 Office E&M - New | Office | 188 | 188 | $61.84 | $12K |
| 17110 Destruction Skin Lesion | Office | 153 | 145 | $70.41 | $11K |
| 99212 Office E&M - Established | Office | 133 | 120 | $35.29 | $4,693 |
| 11103 Skin Biopsy | Office | 115 | 85 | $34.34 | $3,949 |
| 12032 Wound Repair - All Levels | Office | 111 | 99 | $201.58 | $22K |
| 99204 Office E&M - New | Office | 77 | 77 | $92.70 | $7,138 |
| 11602 Skin Lesion Excision | Office | 76 | 68 | $88.27 | $6,709 |
| 11200 Removal or Shaving of Skin Growth | Office | 33 | 33 | $53.41 | $1,762 |
| 69100 Other Organ Systems | Office | 29 | 28 | $50.95 | $1,478 |
By year: 2022 $316K for 7,907 services; 2023 $308K for 6,959 services; 2024 $306K for 7,927 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mark A Mazak prescribed most often to Medicare patients was Triamcinolone Acetonide, with 241 prescriptions and refills. In total Mark A Mazak wrote 1,637 Medicare prescriptions that cost $976K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Triamcinolone Acetonide Generic | 241 | 269 | 160 | $2,658 |
| Ketoconazole Generic | 212 | 247 | 124 | $4,213 |
| Clobetasol Propionate Generic | 132 | 155 | 59 | $6,825 |
| Hydrocortisone Generic | 124 | 142 | 85 | $1,091 |
| Halobetasol Propionate Generic | 110 | 115 | 77 | $3,828 |
| Doxycycline Hyclate Generic | 74 | 96 | 40 | $1,012 |
| Metronidazole Generic | 66 | 83 | 44 | $5,093 |
| Clindamycin Phosphate Generic | 57 | 77 | 29 | $2,510 |
| Mupirocin Generic | 55 | 57 | 48 | $455 |
| Dupixent Pen Dupilumab | 41 | 41 | Under 11 | $154K |
| Mometasone Furoate Generic | 35 | 41 | 24 | $978 |
| Cephalexin Generic | 28 | 30 | 25 | $605 |
| Betamethasone Valerate Generic | 27 | 29 | 18 | $755 |
| Prednisone Generic | 24 | 27 | 21 | $67.58 |
| Valacyclovir Valacyclovir Hcl | 23 | 27 | 17 | $446 |
Brand drugs: 213 claims; generic drugs: 1,424 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark A Mazak $2,125 ($2,125 in general payments such as food, travel and fees) from 17 companies. The largest payer was Journey Medical Corporation with $750.
| Company | Payments | Amount |
|---|---|---|
| Journey Medical Corporation DERM | 1 | $750 |
| Abbvie Inc. ABBV | 24 | $234 |
| Janssen Biotech, Inc. JNJ | 2 | $180 |
| UCB, Inc. UCB.BR | 6 | $161 |
| Amgen Inc. AMGN | 2 | $157 |
| Galderma Laboratories, L.P. GALD.SW | 3 | $129 |
| E.R. Squibb & Sons, L.L.C. BMY | 6 | $98.1 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $90.63 |
| Organon LLC OGN | 6 | $89.01 |
| Mayne Pharma Commercial LLC | 5 | $63.82 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.